

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT VITAFLOW LIBERTY® COMPLETED SEVERAL PRE-MARKET CLINICAL IMPLANTATION CASES IN EUROPE

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed second-generation transcatheter aortic heart valve implantation (“**TAVI**”) product, VitaFlow Liberty® transcatheter aortic valve implantation system (“**VitaFlow Liberty®**”), has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty® is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark.

As the world’s first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty® has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty® received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance.

The successful advancement of VitaFlow Liberty®'s pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty® and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, October 25, 2023

As at the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.